Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Other Working Capital Changes (2020 - 2025)

Barinthus Biotherapeutics' Other Working Capital Changes history spans 6 years, with the latest figure at -$1.5 million for Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 73.96% year-over-year to -$1.5 million; the TTM value through Dec 2025 reached -$2.0 million, up 45.68%, while the annual FY2025 figure was -$2.0 million, 45.68% up from the prior year.
  • Other Working Capital Changes reached -$1.5 million in Q4 2025 per BRNS's latest filing, down from -$156000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $4.8 million in Q4 2023 to a low of -$5.7 million in Q4 2024.
  • Average Other Working Capital Changes over 5 years is -$313647.1, with a median of -$156000.0 recorded in 2025.
  • Peak YoY movement for Other Working Capital Changes: crashed 1674.07% in 2021, then surged 2909.36% in 2023.
  • A 5-year view of Other Working Capital Changes shows it stood at -$11000.0 in 2021, then crashed by 1454.55% to -$171000.0 in 2022, then soared by 2909.36% to $4.8 million in 2023, then crashed by 218.38% to -$5.7 million in 2024, then surged by 73.96% to -$1.5 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Other Working Capital Changes are -$1.5 million (Q4 2025), -$156000.0 (Q3 2025), and $136000.0 (Q2 2025).